PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 4, 2026Micromachines0 citationsOpen Access

Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology

View Full Paper
VAVictor AkpeICIan E. Cock

Key Points

  • This review aims to evaluate the advancements in nanozyme-based biosensors for cancer detection and their potential in precision oncology.
  • Critically assess nanozymes' roles in peroxidase, oxidase, and catalase-like reactions across multiple detection platforms.
  • Discuss smartphone-compatible point-of-care systems and AI-assisted data analysis for improved cancer diagnostics.
  • Evaluate key barriers such as regulatory challenges, reproducibility, and manufacturing scalability.
  • Nanozyme technologies enhance signal generation in cancer biosensing, facilitating multiplexed detection.
  • Next-generation biosensors show potential for early cancer detection and real-time monitoring.
  • Practical considerations for clinical deployment are essential for integrating these advancements into healthcare.

Abstract

This review evaluates recent progress in nanozyme-based biosensors for detecting circulating tumour cells, nucleic acids, and protein biomarkers, with particular attention to how peroxidase-, oxidase-, and catalase-like reactions enhance signal generation across electrochemical, optical, and microfluidic platforms. The roles of iron oxide–gold composites, silica nanostructures, quantum dots, and hybrid nanomaterials in improving analytical performance, enabling multiplexed detection, and facilitating assay miniaturization are critically assessed. Advances such as amplification-free detection approaches, smartphone-compatible point-of-care systems, and AI-assisted data analysis are discussed in relation to their translational potential. Key barriers, including regulatory requirements, reproducibility concerns, and manufacturing scalability, are also evaluated. By integrating mechanistic understanding with practical considerations for clinical deployment, this review outlines how next-generation nanozyme-based biosensors may strengthen early cancer detection, real-time monitoring, and precision oncology.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Akpe et al. (2026) studied this question.

synapsesocial.com/papers/69f836aa3ed186a739980e9ehttps://doi.org/10.3390/mi17050541
Ask AI
Helpful
Bookmark
Share
View Full Paper